Trending News
- Enhanced Recovery after Surgery (Eras) and Immunonutrition: An Evidence-based Approach
- Redhill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to over 40 Million Additional Americans
- Fujifilm Earns Fda “breakthrough Device” Designation for Endosurgical Image Enhancement Technology
- Cognitive Deficit and White Matter Changes in Celiac Disease
- Family History of Colorectal Cancer and Prevalence of Advanced Colorectal Neoplasia in Screening
- Enhanced Recovery after Surgery (Eras) and Immunonutrition: An Evidence-based Approach
- Redhill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to over 40 Million Additional Americans
- Fujifilm Earns Fda “breakthrough Device” Designation for Endosurgical Image Enhancement Technology
- Cognitive Deficit and White Matter Changes in Celiac Disease
- Family History of Colorectal Cancer and Prevalence of Advanced Colorectal Neoplasia in Screening
- Enhanced Recovery after Surgery (Eras) and Immunonutrition: An Evidence-based Approach
- Redhill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to over 40 Million Additional Americans
- Fujifilm Earns Fda “breakthrough Device” Designation for Endosurgical Image Enhancement Technology
- Cognitive Deficit and White Matter Changes in Celiac Disease
- Family History of Colorectal Cancer and Prevalence of Advanced Colorectal Neoplasia in Screening
- This event has passed.
Hepatitis B&C Training Program and Treatment Update 2019 (October)
October 12, 2019
The Scripps National Hepatitis B & C Training Program and Treatment Update will educate health care practitioners on the prevalence, demographics, natural history, prevention, screening, and diagnosis of chronic viral hepatitis, antiviral therapies, histology, cirrhosis, hepatocellular carcinoma, liver biopsy, referral of patients with chronic HBV and/or HCV infection improving their management, and application of multidisciplinary team approach (local network of practitioners).
Lunch non-CME symposium hosted by AbbVie Inc: MAVYRET: Clinical Data Including Real World Evidence